Navigation Links
Clinical trial evaluating brain cancer vaccine is underway at NYU
Date:10/19/2007

NEW YORK, October 18, 2007 A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery and chemotherapy in patients with glioblastoma multiforme, a deadly form of brain cancer.

The vaccine, called DCVax-Brain, incorporates proteins found in patients tumors and is designed to attack cancer cells containing these proteins. The study underway at NYU Medical Center is an expansion of an earlier phase I trial of the vaccine. The vaccine is made by the Northwest Biotherapeutics, Inc., based in Bothell, Washington.

We are really excited about the promise of this vaccine, said Patrick J. Kelly, M.D., the chairman of the Department of Neurosurgery and the Joseph Ransohoff Professor of Neurosurgery at NYU School of Medicine. Everything now depends on something in addition to surgery so that these tumors do not recur. A cancer vaccine like this may make a difference in extending life and maintaining a good quality of life.

This is a form of individualized therapy, adds NYU neuro-oncologist Michael Gruber, M.D. There is a lot of promise with this approach, he says. He and Dr. Kelly will be the lead investigators conducting the trial at NYU.

Despite surgery and chemotherapy, patients with glioblastoma multiforme brain cancer typically survive about 15 months. Even if only a small number of tumor cells are left in the brain, that is enough for these fast growing and aggressive tumors to grow back. The tumors do not grow elsewhere in the body. It is so frustrating, notes Dr. Kelly, because brain tumors dont metastasize like other tumors. They recur locally but we just cant cure it.

A brain cancer vaccine is intended as a kind of immunotherapy, which means that it primes the patients own immune system to kill proteins found in cancer cells. The trial will enroll patients 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard primary treatment with surgery followed by radiation with concurrent chemotherapy. Enrolled patients will be randomized to receive the standard of care, and others will receive the standard of care and the vaccine.

The vaccine will be made from the tumors and immune cells of each patient. When a patients tumor is removed during surgery it will be shipped to a laboratory where the tumor cells will be broken up to prepare the first component of the vaccine. Separately, patients dendritic cells, a powerful type of immune cell, will be obtained and sent to a laboratory for purification. Dendritic cells may be able to teach the immune system to recognize and destroy cancer cells. The patients tumor cell material is combined with the dendritic cells to form the vaccine.


'/>"/>

Contact: Pamela McDonnell
Pamela.Mcdonnell@nyumc.org
212-404-3555
New York University Medical Center and School of Medicine
Source:Eurekalert

Related medicine news :

1. How do patients benefit of clinical trials
2. Magnetic resonance angiography in clinical medicine
3. Clinical trials need to be more frank
4. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
5. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
6. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
7. Clinical Comparisons Between ADHD Drugs Are Less
8. Outsourcing clinical trials to India
9. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
10. India to maintain Public domain Registry database of clinical trials conducted in India.
11. A Novel System For Clinical Banking Of Umbilical Cord Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is ... winter seasons. One major study analyzing heart attacks among 138,602 people recorded a ... a given year. We would all agree of course–no time of year is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: ... trial, not a one hour a week showing of hands. “The Road To Restoration” ... begins, “Perhaps you are familiar with the brass ring that you could reach out ...
(Date:12/7/2016)... Caloifornia (PRWEB) , ... December 07, 2016 , ... ... present the fifth annual Business Architecture Innovation Summit in Reston, VA on March ... world who will share a range of experiences from a cross-section of industries ...
(Date:12/6/2016)... Korea (PRWEB) , ... December 06, 2016 , ... ... Inc. have agreed to collaborate in developing a vaccine against the Middle East ... a vaccine can be available in South Korea for emergency deployment in the ...
(Date:12/6/2016)... ... December 06, 2016 , ... i2i Population Health, a ... a vice president of sales. , “Ajdin understands that building a successful sales ... understand what each client needs, and is persistent in building towards a solution ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; ... program in the use of cannabinoids for the ... June, 2015 InMed initiated its COPD program using ... and potential active compounds that can be useful ... vitro assays using human lung fibroblasts (HFL-1 cell ...
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is an ... is inserted into the femoral artery in the leg ... to treat constricted blood vessels. These products are generally ... atherosclerosis – deposition of lipid substances in the blood ... market is projected to expand at a CAGR of ...
(Date:12/5/2016)... 5, 2016 Spain Glaucoma Surgery Devices Market ... "Spain Glaucoma Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Canaloplasty Micro Catheters and Glaucoma Drainage ... distribution shares data for each of these market segements, ...
Breaking Medicine Technology: